Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
328.80
+4.27 (+1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amgen
< Previous
1
2
3
4
5
Next >
MarketBeat Week in Review – 8/5 - 8/9
August 10, 2024
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Amgen's MariTide Weight Loss Potential: Stock Outlook
August 07, 2024
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning
January 02, 2024
Via
Investor Brand Network
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
4 Oversold Large Cap Stocks Yielding High Dividends
March 14, 2024
Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Amazon Stock: Why it's Finally Included in the Dow Index
February 29, 2024
Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Are these frigid Dow stocks in for a longer winter?
February 08, 2024
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
IBM, Verizon, Merck stocks lead Dow to new highs
January 31, 2024
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
Via
Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Via
FinancialNewsMedia
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
5 Dow stocks to track during the market correction
November 01, 2023
The Dow Jones Industrial Average is struggling in correction territory, but savvy investors keep an eye on resilient stocks like Microsoft, Amgen, and Walmart.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
Via
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Why These 3 Equal-Weighted ETFs Deserve a Portfolio Spot
October 19, 2023
These three equally-weighted exchange traded funds that offer superior diversification and risk adjusted returns are worth a look.
Via
MarketBeat
Topics
ETFs
Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks
October 12, 2023
During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves.
Via
MarketBeat
Topics
ETFs
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.